Importer of Controlled Substances; Notice of Application, 80431-80432 [E8-31079]
Download as PDF
<![CDATA[
80431
Federal Register / Vol. 73, No. 251 / Wednesday, December 31, 2008 / Notices
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Open Systemc Initiative
Notice is hereby given that, on
November 21, 2008, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’) Open
SystemC Initiative (‘‘OSCI’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
Silistix, Manchester, UNITED
KINGDOM has been added as a party to
this venture. Also, BlueSpec Inc.,
Waltham, MA has withdrawn as a party
to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and OSCI intends
to file additional written notifications
disclosing all changes in membership.
On October 9, 2001, OSCI filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on January 3, 2002 (67 FR 350).
The last notification was filed with
the Department on March 25, 2008. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on May 9, 2008 (73 FR 26415).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. E8–31040 Filed 12–30–08; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Antitrust Division
pwalker on PROD1PC71 with NOTICES
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Petroleum Environmental
Research Forum
Notice is hereby given that, on
November 26, 2008, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’), the
Petroleum Environmental Research
Forum (‘‘PERF’’) has filed written
notifications simultaneously with the
VerDate Aug<31>2005
17:41 Dec 30, 2008
Jkt 217001
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Veolia Water North
America Operating Services, Inc.,
Chicago, IL has been added as a party
to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and PERF intends
to file additional written notifications
disclosing all changes in membership.
On February 10, 1986, PERF filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on March 14, 1986 (51 FR 8903).
The last notification was filed with
the Department on July 9, 2008. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on July 31, 2008 (73 FR 44773).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. E8–31038 Filed 12–30–08; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on October 29, 2008,
Norac Inc., 405 S. Motor Avenue, P.O.
Box 577, Azusa, California 91702–3232,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Tetrahydrocannabinols
(7370), a basic class of controlled
substance listed in schedule I.
The company plans to manufacture
the listed controlled substance in bulk
for formulation into the pharmaceutical
controlled substance Marinol® for sale
to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 2, 2009.
Dated: December 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–31084 Filed 12–30–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations 1301.34(a),
this is notice that on October 14, 2008,
Johnson Matthey Inc., Pharmaceutical
Materials, 2003 Nolte Drive, West
Deptford, New Jersey 08066–1742, has
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
Thebaine (9333) ...........................
Noroxymorphone (9668) ..............
Schedule
II
II
The company plans to import
analytical reference standards for
distribution to its customers for research
purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, Virginia 22152; and
E:\FR\FM\31DEN1.SGM
31DEN1
80432
Federal Register / Vol. 73, No. 251 / Wednesday, December 31, 2008 / Notices
must be filed no later than January 30,
2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, (40 FR 43745–46), all applicants
for registration to import the basic class
of any controlled substance in schedule
I or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: December 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–31079 Filed 12–30–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on
November 4, 2008, Johnson Matthey,
Inc., Pharmaceutical Materials, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
II:
pwalker on PROD1PC71 with NOTICES
Drug
Schedule
Phenylacetone (8501) ..................
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
II
II
II
The company plans to import the
listed controlled substances as raw
materials for use in the manufacture of
VerDate Aug<31>2005
17:41 Dec 30, 2008
Jkt 217001
bulk controlled substances for
distribution to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 30, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: December 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–31080 Filed 12–30–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated September 22, 2008,
and published in the Federal Register
on September 29, 2008, (73 FR 56611),
GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois
60004–1412, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Cocaine (9041), a basic
class of controlled substance listed in
schedule II.
The company plans to import small
quantities of ioflupane, in the form of
three separate analogues of Cocaine, to
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
validate production and QC systems; for
a reference standard; and for producing
material for future investigational new
drug (IND) submission.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
GE Healthcare to import the basic class
of controlled substance is consistent
with the public interest, and with
United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated GE
Healthcare to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: December 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–31081 Filed 12–30–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Submission for OMB Review:
Comment Request
December 19, 2008.
The Department of Labor (DOL)
hereby announces the submission of the
following public information collection
request (ICR) to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995
(Pub. L. 104–13, 44 U.S.C. chapter 35).
A copy of this ICR, with applicable
supporting documentation; including
among other things a description of the
likely respondents, proposed frequency
of response, and estimated total burden
may be obtained from the RegInfo.gov
Web site at https://www.reginfo.gov/
public/do/PRAMain or by contacting
Mary Beth Smith-Toomey on 202–693–
4223 (this is not a toll-free number)/email: DOL_PRA_PUBLIC@dol.gov.
Interested parties are encouraged to
send comments to the Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for the
E:\FR\FM\31DEN1.SGM
31DEN1
]]>Agencies
[Federal Register Volume 73, Number 251 (Wednesday, December 31, 2008)]
[Notices]
[Pages 80431-80432]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-31079]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
registration under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
1301.34(a), this is notice that on October 14, 2008, Johnson Matthey
Inc., Pharmaceutical Materials, 2003 Nolte Drive, West Deptford, New
Jersey 08066-1742, has made application by letter to the Drug
Enforcement Administration (DEA) to be registered as an importer of the
basic classes of controlled substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Thebaine (9333)............................ II
Noroxymorphone (9668)...................... II
------------------------------------------------------------------------
The company plans to import analytical reference standards for
distribution to its customers for research purposes.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43, and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
8701 Morrissette Drive, Springfield, Virginia 22152; and
[[Page 80432]]
must be filed no later than January 30, 2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR Sec. 1301.34(b),
(c), (d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import the basic class of any controlled
substance in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: December 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-31079 Filed 12-30-08; 8:45 am]
BILLING CODE 4410-09-P
